A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
Known as the most common form of kidney cancer in adults, renal cell carcinoma (RCC) has seen an influx of research in recent weeks. Here, CURE
® looks back at some of the latest news and updates in the RCC space.
For more RCC coverage go here.
- Data presented at the 2020 ASCO Virtual Scientific Meeting demonstrated that MK-6482 appeared to be well tolerated and induced clinical responses among patients with VHL–associated RCC.
- Updated study results also presented during the 2020 ASCO Virtual Scientific Meeting showed that Keytruda (pembrolizumab) in combination with Inlyta (axitinib) continued to demonstrate significant improvements in progression-free survival (PFS) and overall survival (OS) compared to Sutent (sunitinib) in patients with previously untreated, advanced RCC.
- A recent feature in CURE®’s Immunotherapy issue highlights how advances in a variety of novel treatments, including immunotherapies, are extending life in patients with advanced kidney cancer.
- Patients with advanced, previously untreated RCC may soon have a new option in the form of the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to study results from the phase 3 CheckMate-9ER trial.
- The Food and Drug Administration’s recent approval of a higher recommended dose of Keytruda (pembrolizumab) every six weeks for adults across all cancer types, in which the drug is indicated for, is a welcomed change for patients.